Patents by Inventor Trevor J. McFarland

Trevor J. McFarland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RTEF-1 variants and the use thereof for inhibition of angiogenesis
    Patent number: 9937269
    Abstract: Dominant negative (DN) variants of transcriptional enhancer factor 1-related (RTEF-1) are described. DN RTEF-1 polypeptides may be directly targeted to cells or delivered in nucleic acid expression vectors to alter cellular transcription. Methods for inhibiting VEGF production and thereby treating angiogenic disorders such as cancer are described. For example, in certain aspects, DN RTEF-1 may be used to treat angiogenic disorders of the eye such as age related macular degeneration (AMD).
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: April 10, 2018
    Assignee: Research Development Foundation
    Inventors: J. Timothy Stout, Trevor J. McFarland, Binoy Appukuttan
  • RTEF-1 VARIANTS AND THE USE THEREOF FOR INHIBITION OF ANGIOGENESIS
    Publication number: 20170081377
    Abstract: Dominant negative (DN) variants of transcriptional enhancer factor 1-related (RTEF-1) are described. DN RTEF-1 polypeptides may be directly targeted to cells or delivered in nucleic acid expression vectors to alter cellular transcription. Methods for inhibiting VEGF production and thereby treating angiogenic disorders such as cancer are described. For example, in certain aspects, DN RTEF-1 may be used to treat angiogenic disorders of the eye such as age related macular degeneration (AMD).
    Type: Application
    Filed: December 5, 2016
    Publication date: March 23, 2017
    Applicant: Research Development Foundation
    Inventors: J. Timothy STOUT, Trevor J. McFARLAND, Binoy APPUKUTTAN
  • STY PEPTIDES FOR INHIBITION OF ANGIOGENESIS
    Publication number: 20170037091
    Abstract: Peptides for the treatment of cancer and angiogenic disorders are provided. In some aspects, the peptides may be used to decrease angiogenesis or VEGF expression or function in a cancer such as, e.g., an ocular cancer. In some embodiments, a peptide of the present invention may be used to treat an angiogenic eye disorder such as, e.g., diabetic retinopathy.
    Type: Application
    Filed: February 25, 2015
    Publication date: February 9, 2017
    Applicant: Research Development Foundation
    Inventors: Tim STOUT, Bissan AHMED, Binoy APPUKUTTAN, Trevor J. McFARLAND
  • RTEF-1 variants and the use thereof for inhibition of angiogenesis
    Patent number: 9512423
    Abstract: Dominant negative (DN) variants of transcriptional enhancer factor 1-related (RTEF-1) are described. DN RTEF-1 polypeptides may be directly targeted to cells or delivered in nucleic acid expression vectors to alter cellular transcription. Methods for inhibiting VEGF production and thereby treating angiogenic disorders such as cancer are described. For example, in certain aspects, DN RTEF-1 may be used to treat angiogenic disorders of the eye such as age related macular degeneration (AMD).
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: December 6, 2016
    Assignee: Research Development Foundation
    Inventors: J. Timothy Stout, Trevor J. McFarland, Binoy Appukuttan
  • RTEF-1 VARIANTS AND THE USE THEREOF FOR INHIBITION OF ANGIOGENESIS
    Publication number: 20140322205
    Abstract: Dominant negative (DN) variants of transcriptional enhancer factor 1-related (RTEF-1) are described. DN RTEF-1 polypeptides may be directly targeted to cells or delivered in nucleic acid expression vectors to alter cellular transcription. Methods for inhibiting VEGF production and thereby treating angiogenic disorders such as cancer are described. For example, in certain aspects, DN RTEF-1 may be used to treat angiogenic disorders of the eye such as age related macular degeneration (AMD).
    Type: Application
    Filed: May 5, 2014
    Publication date: October 30, 2014
    Applicant: RESEARCH DEVELOPMENT FOUNDATION
    Inventors: J. Timothy STOUT, Trevor J. MCFARLAND, Binoy APPUKUTTAN
  • RTEF-1 variants and the use thereof for inhibition of angiogenesis
    Patent number: 8748379
    Abstract: Dominant negative (DN) variants of transcriptional enhancer factor 1-related (RTEF-1) are described. DN RTEF-1 polypeptides may be directly targeted to cells or delivered in nucleic acid expression vectors to alter cellular transcription. Methods for inhibiting VEGF production and thereby treating angiogenic disorders such as cancer are described. For example, in certain aspects, DN RTEF-1 may be used to treat angiogenic disorders of the eye such as age related macular degeneration (AMD).
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: June 10, 2014
    Assignee: Research Development Foundation
    Inventors: J. Timothy Stout, Trevor J. McFarland, Binoy Appukuttan
  • RTEF-1 VARIANTS AND THE USE THEREOF FOR INHIBITION OF ANGIOGENESIS
    Publication number: 20090117119
    Abstract: Dominant negative (DN) variants of transcriptional enhancer factor 1-related (RTEF-1) are described. DN RTEF-1 polypeptides may be directly targeted to cells or delivered in nucleic acid expression vectors to alter cellular transcription. Methods for inhibiting VEGF production and thereby treating angiogenic disorders such as cancer are described. For example, in certain aspects, DN RTEF-1 may be used to treat angiogenic disorders of the eye such as age related macular degeneration (AMD).
    Type: Application
    Filed: June 6, 2008
    Publication date: May 7, 2009
    Inventors: J. Timothy Stout, Trevor J. McFarland, Binoy Appukuttan